HollisEden Pharmaceuticals News

Hollis-Eden Pharmaceuticals, Inc. today announced additional positive interim data from its on-going Phase I/II clinical trial with its investigational oral drug candidate TRIOLEX , supporting the potential ...

Hollis-Eden Pharmaceuticals, Inc. is developing a proprietary new class of compounds that are metabolites or synthetic analogs of adrenal steroid hormones. via BioSpace

“This newly released preclinical data is exciting and timely as we are about to commence our Phase I/II clinical trial with APOPTONE in late-stage prostate cancer patients”

Apr 14, 2008 - Hollis-Eden Pharmaceuticals, Inc. , the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced the presentation today of ... via Med Ad News

Hollis-Eden Pharmaceuticals, Inc. today announced positive preliminary data from its ongoing 28-day Phase I/II clinical trial in obese insulin resistant subjects with its investigational drug candidate TRIOLEX ... via Earth Times

“The response to this new pain relieving cream, the first of its kind with ginger, continues to be very positive. We continue being a best selling topical pain reliever at those locations. ”

RealPennies.com: Turning Pennies into dollars: , , , . RDATE:08022008 Are you a public company looking for exposure? Contact RealPennies.com - 1.800.940.6559 For more info: http://hsxi.realpennies.com ... via TMCnet

“APOPTONE represents a potentially exciting, novel hormone-based cytotoxic treatment for prostate cancer patients as well as other hormone sensitive cancers, such as breast cancer”

Scott Rieger, Director, Corporate Communications 858-587-9333 Hollis-Eden Pharmaceuticals, Inc. via PR-inside.com

Hollis-Eden Hollis-Eden Pharmaceuticals, Inc. , the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, today announced that it will present ... via Freshnews

Redpoint Bio Corporation , a company developing ingredients to improve the taste of pharmaceutical, food and beverage products, today announced - 12/20/2007 - 07:00 AM SAN DIEGO-- --Hollis-Eden Pharmaceuticals, ... via Business Wire

“We look forward to continuing successes in our collaboration to bring novel anti-inflammatory therapies to CF patients.”

Scott Rieger, Director, Corporate Communications 858-587-9333 or Cystic Fibrosis Foundation Laurie Fink, Director of Media Relations, 301-841-2602 Hollis-Eden Pharmaceuticals, Inc. via PR-inside.com

“Time is a great teacher, but unfortunately it kills all its pupils.”

December 11, 2007 Conference calls scheduled at 11 a.m. to 2:55 p.m. on Investrend Broadcast via partner BestCalls include WellPoint Health Networks Inc. via Customer Interaction Solutions

Drug stocks largely hugged the flat line early action Monday as shares of Atherogenics Inc. via MarketWatch

The Nasdaq Stock Market, Inc. announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index , which will become effective with the market open on Monday, November 19, 2007. via PrimeNewswire

“Advancing TRIOLEX into a Phase I/II human clinical trial is a significant achievement for our development program targeting metabolic disorders”

Hollis-Eden Pharmaceuticals Commencing Phase I/II Clinical Trial with TRIOLEX in Obese, Insulin Resistant Volunteers Hollis-Eden Pharmaceuticals, Inc. via Freshnews

The small-cap sector mimicked the choppy broad indices and traded little changed Thursday, despite some big moves among individual names. via TheStreet.com

Development-stage biopharmaceutical company Hollis-Eden Pharmaceuticals garnered investor enthusiasm after presenting encouraging preclinical data on its prostate cancer drug candidate HE3235. via TheStreet.com

Hollis-Eden Pharmaceuticals, Inc.'s prostate cancer drug inhibits tumor growth, the San Diego-based company announced before the opening. via All Stories

EQUITIES Magazine proudly announces its Second Annual Transatlantic Conference, to be held at the NASDAQ MarketSite in New York City on Sept. via Market Wire

Drug stocks moved into positive territory midday Wednesday, with shares of Amgen Inc. via MarketWatch